Nov 2014 to 2000 Copy Editor/ProofreaderWolverine Press Ann Arbor, MI Jan 2014 to Aug 2014 ApprenticeUniversity of Michigan Ann Arbor, MI Jan 2014 to May 2014 Thesis AdviserUniversity of Michigan Ann Arbor, MI May 2013 to May 2014 Zell FellowUniversity of Michigan Ann Arbor, MI Sep 2011 to May 2013 Graduate Student InstructorJanklow & Nesbit Associates New York, NY Oct 2009 to Aug 2011 Foreign Contracts CoordinatorJanklow & Nesbit Associates New York, NY Nov 2007 to Oct 2009 Permissions and Contracts AssistantCanteen Magazine Brooklyn, NY Jul 2007 to Jan 2008 Editorial AssistantGoGORILLA Media New York, NY Jun 2007 to Aug 2007 Editorial Intern
Education:
University of Michigan, Helen Zell Writers' Program Ann Arbor, MI 2011 to 2013 MFA in FictionMuhlenberg College Allentown, PA 2003 to 2007 BA in English with Creative Writing Concentration
Us Patents
Serum-Free, Low-Protein Media For Rotavirus Vaccine Production
Sandra L. Gould - Tinton Falls NJ David K. Robinson - New York NY Daniel J. Distefano - Cranford NJ T. Craig Seamans - Westfield NJ
Assignee:
Merck Co., Inc. - Rahway NJ
International Classification:
C12N 700
US Classification:
4352351, 4242131, 4241841
Abstract:
Defined serum-free, low protein media (LPKM), that supports 1) Vero cell growth for up to 20 passages, 2) Vero cell growth on microcarriers and 3) rotavirus production is provided. Maximum cell densities attained are 60-100% of that in serum-containing medium; the doubling time is equal to that for cells in serum containing medium. Rotavirus titers achieved in LPKM-1 are 50-100% of the serum-containing process. Finally, since LPKM-1 contains no animal-sourced proteins, the problems associated with the serum-containing rotavirus production process (i. e. lengthy wash steps before infection, potential introduction of adventitious agents and lot-to-lot variability) can be avoided; while maintaining nearly equivalent product titers.